Retension Pharmaceuticals (RTSN) CEO L. Buys $250K of Stock
Eric L. Keller purchased 20,800 shares of Retension Pharmaceuticals for $249,600 on October 13, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Keller Eric L., CHIEF EXECUTIVE OFFICER at Retension Pharmaceuticals, Inc. ($RTSN), bought 20,800 shares at an average price of $12, worth about $249,600, on October 13, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RTSN is up 21.0% to date (from the $11.63 close on Oct 13, 2026).
RTSN
Retension Pharmaceuticals, Inc.
Key Points
- On October 13, 2026, CEO Eric L. Keller bought 20,800 shares of Retension Pharmaceuticals, Inc. at $12.00 each, totaling $249,600.
- The stock recently traded around $13.27, which is about 15.7% above its 50-day and 200-day moving averages.
- Director Franklin M. Berger also bought 10,000 shares on the same day for $120,000, reflecting insider confidence.
Get $RTSN trade alerts by text
We text you when insiders, Congress or big funds trade $RTSN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Retension Pharmaceuticals, Inc. alert may contain errors. Disclosures
On October 13, 2026, Eric L. Keller, the Chief Executive Officer of Retension Pharmaceuticals, Inc. (RTSN) on the NasdaqCM, bought 20,800 shares at $12.00 each, totaling $249,600. This purchase comes as the stock has been trading above its key moving averages.
Inside Keller's Trade
Keller's purchase adds to his stake in Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and cardiovascular diseases. The shares he bought are part of a larger effort to bolster the company's leadership presence in the market. The total value of his recent acquisition stands at $249,600, reflecting a commitment to the company's future.
Other Institutional Activity in Retension Pharmaceuticals
On the same day as Keller's trade, Director Franklin M. Berger also made a significant move by buying 10,000 shares at $12.00 each, totaling $120,000. This simultaneous activity among top executives might suggest a shared confidence in the company's direction.
Retension Pharmaceuticals, Inc. Stock Up 8.6%
As of October 16, 2026, Retension Pharmaceuticals traded recently around $13.27. This price is about 15.7% above both its 50-day and 200-day moving averages, signaling positive momentum. However, the stock is still about 11.4% below its 52-week high of $14.97, indicating potential room for growth.
Recent Earnings
The company reported a trailing twelve-month EPS of -$2.61, reflecting its status as a clinical-stage firm still in development. No upcoming earnings date is currently noted, but investors will be watching for further updates as the company progresses.
Insider Buying and Selling at Retension Pharmaceuticals, Inc.
In addition to Keller's purchase, Director Franklin M. Berger bought 10,000 shares on the same day for $120,000. These trades highlight a proactive approach from the company's leadership amid its ongoing development efforts.
About Retension Pharmaceuticals
Retension Pharmaceuticals, Inc. is a biopharmaceutical company based in Falls Church, Virginia. It specializes in developing treatments for hypertension and other cardiovascular diseases, with its lead product RTN-001 aimed at improving blood pressure through nitric oxide signaling. The company has been operational since its incorporation in 2023, and its leadership's recent buying activity may signal confidence in its growth trajectory.
Bottom Line
Investors will be keen to see how Retension Pharmaceuticals continues to develop its product pipeline. With Keller and Berger making recent purchases, there may be more insights into the company's future performance as new developments unfold.
Related Filing Alerts
Source: Keller Eric L.'s Form 4 filing on $RTSN (Oct 13, 2026). Find the original filing: RTSN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts